These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22264050)

  • 21. Microbicide delivery: formulation technologies and strategies.
    Romano J; Malcolm RK; Garg S; Rohan LC; Kaptur PE
    Curr Opin HIV AIDS; 2008 Sep; 3(5):558-66. PubMed ID: 19373022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides.
    Fetherston SM; Malcolm RK; Woolfson AD
    Ther Deliv; 2010 Dec; 1(6):785-802. PubMed ID: 22834014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Microbicides for preventing sexually transmitted infections: Current status and strategies for preclinical evaluation of new candidates].
    Fernández Romero JA; Gil PI; Ré V; Robbiani M; Paglini G
    Rev Argent Microbiol; 2014; 46(3):256-68. PubMed ID: 25444135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rectal pre-exposure prophylaxis (PrEP).
    Rohan LC; Yang H; Wang L
    Antiviral Res; 2013 Dec; 100 Suppl(0):S17-24. PubMed ID: 24188705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances on anti-HIV vaginal delivery systems development.
    Antimisiaris SG; Mourtas S
    Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-specific microbicide product development: then and now.
    Romano JW; Robbiani M; Doncel GF; Moench T
    Curr HIV Res; 2012 Jan; 10(1):9-18. PubMed ID: 22264041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravaginal gels as drug delivery systems.
    Justin-Temu M; Damian F; Kinget R; Van Den Mooter G
    J Womens Health (Larchmt); 2004 Sep; 13(7):834-44. PubMed ID: 15385078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.
    Carballo-Diéguez A; Giguere R; Dolezal C; Bauermeister J; Leu CS; Valladares J; Rohan LC; Anton PA; Cranston RD; Febo I; Mayer K; McGowan I
    AIDS Behav; 2014 Sep; 18(9):1734-45. PubMed ID: 24858481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.
    Ham AS; Nugent ST; Peters JJ; Katz DF; Shelter CM; Dezzutti CS; Boczar AD; Buckheit KW; Buckheit RW
    Antiviral Res; 2015 Aug; 120():153-64. PubMed ID: 26093158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmaceutical development of microbicide drug products.
    Friend DR
    Pharm Dev Technol; 2010 Dec; 15(6):562-81. PubMed ID: 20017601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential use of protease inhibitors as vaginal and colorectal microbicides.
    Herrera C; Shattock RJ
    Curr HIV Res; 2012 Jan; 10(1):42-52. PubMed ID: 22264045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?
    das Neves J; Amiji M; Sarmento B
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(4):389-99. PubMed ID: 21506290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reverse transcriptase inhibitors as microbicides.
    Lewi P; Heeres J; Ariën K; Venkatraj M; Joossens J; Van der Veken P; Augustyns K; Vanham G
    Curr HIV Res; 2012 Jan; 10(1):27-35. PubMed ID: 22264043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving topical microbicide applicators for use in resource-poor settings.
    Vail JG; Cohen JA; Kelly KL
    Am J Public Health; 2004 Jul; 94(7):1089-92. PubMed ID: 15226124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system.
    Machado A; Cunha-Reis C; Araújo F; Nunes R; Seabra V; Ferreira D; das Neves J; Sarmento B
    Acta Biomater; 2016 Oct; 44():332-40. PubMed ID: 27544812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming recruitment challenges: lessons learned from a safety and feasibility study of a diaphragm/microbicide combination in South Africa.
    Guest G; Severy L; von Mollendorf C; Van Damme L
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):481-2. PubMed ID: 17622839
    [No Abstract]   [Full Text] [Related]  

  • 37. Electrospun fibers for vaginal anti-HIV drug delivery.
    Blakney AK; Ball C; Krogstad EA; Woodrow KA
    Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV.
    Ball C; Woodrow KA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4855-65. PubMed ID: 24913168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.
    Buckheit KW; Furlan-Freguia C; Ham AS; Buckheit RW
    Curr Top Med Chem; 2016; 16(10):1118-34. PubMed ID: 26324047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.
    Patton DL; Sweeney YT; Paul KJ
    Sex Transm Dis; 2009 Jun; 36(6):350-6. PubMed ID: 19556929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.